Educational reference only. Not medical advice. Research compounds are not for human or veterinary use.

GLP-1 drugs: benefits and side effects

GLP-1 drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have changed how obesity and type 2 diabetes are treated. They are also among the most studied drugs in the world, so we know a lot about what they do well, what they cost the body and where the open questions are. Here is a plain-language summary of the benefits and the side effects, based on the major trials and the FDA labels.

What GLP-1 drugs are

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It tells the pancreas to release insulin when blood sugar is high, lowers glucagon, slows how fast the stomach empties and acts on appetite centers in the brain. The natural hormone lasts only minutes. The drugs are modified versions that last days, so they can be given once a week.

  • Semaglutide activates the GLP-1 receptor.
  • Tirzepatide activates both the GLP-1 and GIP receptors, which is why it is called a dual agonist. See our tirzepatide brief.
  • Orforglipron (Foundayo) is a newer once-daily pill. It activates the GLP-1 receptor but is a small molecule, not a peptide.

Where they stand with the FDA

  • Semaglutide: approved as Ozempic for type 2 diabetes (2017), as Wegovy for chronic weight management (2021), for lowering heart attack, stroke and cardiovascular death risk in adults with heart disease and excess weight (2024), as Ozempic for kidney protection in type 2 diabetes with chronic kidney disease (January 2025), and as Wegovy for the liver disease MASH with moderate to advanced fibrosis (August 2025). A once-daily Wegovy pill was approved in December 2025.
  • Tirzepatide: approved as Mounjaro for type 2 diabetes (2022), as Zepbound for chronic weight management (2023), and for obstructive sleep apnea in adults with obesity (December 2024).
  • Orforglipron: approved as Foundayo for weight management on April 1, 2026.
  • Not approved: retatrutide, which Lilly plans to submit to the FDA in early 2027, and the cagrilintide and semaglutide combination CagriSema, which is still under FDA review as of this writing. See our cagrilintide brief.

The benefits

Weight loss

  • Semaglutide: in the STEP-1 trial, adults with obesity lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% on placebo.
  • Tirzepatide: in SURMOUNT-1, average weight loss over 72 weeks ranged from 15.0% on the lowest dose to 20.9% on the highest, compared with 3.1% on placebo.
  • Pills: in the trial behind the Wegovy pill, people lost 16.6% on average over 64 weeks versus 2.7% on placebo, a figure based on people who kept taking it. In ATTAIN-1, orforglipron produced up to 11.1% weight loss at 72 weeks versus 2.1% on placebo.

These are averages. Some people lose far more and some lose little.

Heart, kidneys, liver and sleep

The bigger story of the last few years is that the benefits reach beyond the scale:

  • Heart: the SELECT trial followed 17,604 adults with heart disease and excess weight but no diabetes. Semaglutide cut the rate of heart attack, stroke or cardiovascular death by 20% (6.5% versus 8.0%).
  • Heart failure: in SUMMIT, tirzepatide lowered the risk of cardiovascular death or worsening heart failure by 38% in 731 people with obesity and heart failure with preserved ejection fraction.
  • Kidneys: in FLOW, semaglutide lowered the risk of serious kidney disease events by 24% in people with type 2 diabetes and chronic kidney disease.
  • Liver: in ESSENCE, MASH resolved without worsening scarring in 62.9% of people on semaglutide versus 34.3% on placebo.
  • Sleep apnea: in SURMOUNT-OSA, tirzepatide reduced breathing interruptions by about 25 per hour, compared with about 5 on placebo, in people not using a CPAP machine.

Blood sugar

In type 2 diabetes, GLP-1 drugs lower A1C substantially. Tirzepatide lowered A1C more than semaglutide in a head-to-head trial (SURPASS-2).

The side effects

Stomach and gut effects are the most common

  • In STEP-1, 74.2% of people on semaglutide reported gastrointestinal side effects, compared with 47.9% on placebo. The Wegovy label lists nausea in 44% versus 16%.
  • In SURMOUNT-1, nausea affected 25% to 33% of people on tirzepatide (9.5% on placebo), with diarrhea, vomiting and constipation also common.
  • These effects are usually mild to moderate and most common while the dose is being increased. Still, 7.0% of people on semaglutide in STEP-1 and 4% to 7% on tirzepatide in SURMOUNT-1 stopped treatment because of side effects.

Warnings on the label

The FDA labels for these drugs carry:

  • A boxed warning about thyroid C-cell tumors. These were seen in rodents, and it is not known whether they occur in people. The drugs should not be used by anyone with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2).
  • Pancreatitis and gallbladder disease, including gallstones.
  • Low blood sugar, mainly when combined with insulin or a sulfonylurea.
  • Kidney injury from dehydration caused by vomiting or diarrhea.
  • Diabetic retinopathy complications in people with type 2 diabetes.
  • A faster heart rate.
  • Aspiration during anesthesia or deep sedation, added to all GLP-1 labels in November 2024 because food can stay in a slowed stomach. Tell any surgeon or anesthesiologist that you take one.
  • Bowel obstruction, including ileus and severe constipation, reported after approval.

A new eye warning

NAION (non-arteritic anterior ischemic optic neuropathy) is a sudden loss of blood flow to the optic nerve that can cause permanent vision loss in one eye. In June 2025, the European Medicines Agency concluded it is a very rare side effect of semaglutide, affecting up to 1 in 10,000 people. On November 9, 2026, the FDA announced it is requiring a warning about a potential NAION risk on the labels of all GLP-1 drugs, including tirzepatide and orforglipron. In the FDA's analysis of 126 clinical trials, NAION occurred at 6.4 cases per 100,000 person-years on GLP-1 drugs versus 3.8 on comparators. The risk is small, but sudden vision changes need urgent medical attention.

A warning that was removed

The weight-loss labels for Wegovy, Zepbound and Saxenda used to warn about suicidal thoughts, a precaution carried over from older weight-loss drugs. In January 2026 the FDA asked for that warning to be removed after reviewing 91 placebo-controlled trials with about 108,000 patients and a real-world study of about 2.2 million people, which found no increased risk. Anyone who notices new or worsening depression on any medicine should still talk to their clinician.

Weight regain after stopping

GLP-1 drugs treat a chronic condition; they do not cure it. When people in STEP-1 stopped semaglutide, they regained about two-thirds of the weight they had lost within a year. In SURMOUNT-4, people switched from tirzepatide to placebo regained 14% of their body weight, while those who stayed on it kept losing.

Muscle and lean mass

Some of the weight lost on any diet is lean tissue, and GLP-1 drugs are no exception. In a small STEP-1 body-composition substudy, lean mass made up roughly 39% of the weight lost. In SURMOUNT-1, fat mass fell about three times as much as lean mass in percentage terms, so body composition improved overall. Whether the lean loss matters for strength and long-term health, especially in older adults, is an active research question, and protein intake and resistance training are often recommended alongside treatment.

Pregnancy and birth control

GLP-1 drugs are not recommended during pregnancy, and the Wegovy label advises stopping semaglutide at least two months before a planned pregnancy. Tirzepatide can make birth-control pills less reliable, especially after starting and after each dose increase, so its label recommends a non-oral method or a backup method for a time.

Compounded, counterfeit and "research" GLP-1s

  • Compounding: pharmacies could make copies of semaglutide and tirzepatide while the drugs were on the FDA shortage list. The FDA declared the tirzepatide shortage over in December 2024 and the semaglutide shortage over in February 2025, which ended that broad allowance after a wind-down period.
  • Dosing errors: the FDA has reported people giving themselves five to 20 times the intended dose of compounded semaglutide after confusing milliliters, milligrams and syringe "units."
  • Counterfeits: in April 2025 the FDA warned about counterfeit Ozempic pens found in the U.S. supply chain.
  • "Research use only" vials: in warning letters dated March 31 and August 24, 2026, the FDA told online sellers of research-labeled semaglutide, tirzepatide and retatrutide that, despite their labels, the evidence on their websites showed the products were intended as drugs for human use. Research-grade material is not the approved drug and has not been evaluated for quality or safety. For what independent testing has found, see grey-market vs. compounded peptides.

The bottom line

GLP-1 drugs produce real, large weight loss and, in major trials, lower the risk of heart, kidney and liver complications. The trade-offs are common stomach side effects, rare but serious risks spelled out on the label, a likely need for long-term treatment, and some loss of lean mass. Approved versions require a prescription, and the decision to start, change or stop one belongs with a clinician who knows your history.

Key references

This post is educational. It does not give dosing guidance, and it is not a substitute for advice from a clinician who knows your medical history.

Educational content only

Peptide Knowledge is an educational reference. Nothing on this site is medical advice, a treatment recommendation or dosing guidance. Many compounds described here are not approved for human use and are sold for laboratory research only. Talk to a licensed clinician before starting, stopping or changing any medication or supplement.

All blog posts